Brief: UK's MHRA Approves Rilzabrutinib To Treat Adults With Immune Thrombocytopenia
29/05/2026 12:31
BRIEF-UK's MHRA Approves Rilzabrutinib To Treat Adults With Immune Thrombocytopenia May 29 (Reuters) - UK's MHRA:
UK'S MHRA: RILZABRUTINIB AUTHORISED TO TREAT ADULTS WITH IMMUNE THROMBOCYTOPENIA WHEN PRIOR TREATMENTS HAVE BEEN INSUFFICIENT
Further company coverage: SASY.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sanofi SA
See all newsFDA approves expanded use of Sanofi's type 1 diabetes drug (updated)
Brief: FDA Approves Tzield For Pediatric Stage 3 Type I Diabetes
FDA approves Sanofi's drug for stage 3 type 1 diabetes in children
European shares steady as investors weigh US-Iran flare-up (updated)
European shares steady as investors cling to Mideast peace hopes